The Patent Finder

Nuvisan Icb GmbH

Also on record
Records under this name other than patents Nuvisan Icb GmbH holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Showing 1 to 4 of 4 · Back to Nuvisan Icb GmbH

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 11,964,953Substituted Aminothiazoles as Dgkzeta Inhibitors for Immune Activation
In force
 · High confidence
In forceHigh confidence
US 12,760,047Phosphorus Derivatives as SOS1 Inhibitors
In force
 · High confidence
In forceHigh confidence
18/275,978MAP4K1 Inhibitors
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/871,455IMIDAZO(1,2-1)PYRIDINE Derivatives as RIPK2 Inhibitors
now held by Mirador Therapeutics, Inc.
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited